Paclitaxel, ifosfamide and cisplatin with granulocyte colony-stimulating factor or recombinant human interleukin 3 and granulocyte colony-stimulating factor in ovarian cancer: a feasibility study.

The tolerability and efficacy of four courses of paclitaxel and ifosfamide plus cisplatin every 3 weeks was evaluated in patients with residual or refractory ovarian cancer. Additionally, supportive haematological effects of recombinant human interleukin 3 (rhIL-3) and recombinant human granulocyte...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Veldhuis, G. J., Willemse, P. H., Beijnen, J. H., Boonstra, H., Piersma, H., van der Graaf, W. T., de Vries, E. G.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Nature Publishing Group|1 1997
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2063352/
https://ncbi.nlm.nih.gov/pubmed/9043028
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak